161 related articles for article (PubMed ID: 35383703)
1. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.
Liu CY; Lin HF; Lai WY; Lin YY; Lin TW; Yang YP; Tsai FT; Wang CL; Luo YH; Chen YM; Hsu PK; Kai LJ; Kiat AOH; Chien Y; Chiou SH; Wang CY
J Chin Med Assoc; 2022 Apr; 85(4):409-413. PubMed ID: 35383703
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
3. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
5. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
[TBL] [Abstract][Full Text] [Related]
7. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
11. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Gao J; Li HR; Jin C; Jiang JH; Ding JY
Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
[TBL] [Abstract][Full Text] [Related]
12. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.
Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
[TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Qu GP; Shi M; Wang D; Wu JH; Wang P; Gong ML; Zhang ZJ
BMC Pulm Med; 2021 Jul; 21(1):208. PubMed ID: 34210314
[TBL] [Abstract][Full Text] [Related]
15. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
16. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
17. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
19. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
20. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
